Carlos Vives Alvarado, MD
Ophthalmology · Rio Piedras, PRNPI 1902207459
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 98.7% of the total across 31 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 9 manufacturers reported payments, led by AbbVie at 41.0% of the total. Reporting peaked in 2024 at $590 and has fallen 50.0% since, to $295 in 2025.
Across 31 payments — averaging $52.53 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$667
- Bausch & Lomb Americas Inc.$269
- NEW World Medical,inc.$185
- Aerie Pharmaceuticals, Inc.$139
- Rxsight Inc$105
- Alcon Puerto Rico Inc$86
- plus $177 from 3 others
What the payments were for
- Food & beverage$1,60799%
- Education$221%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 11 | $667 |
| Bausch & Lomb Americas Inc. | 10 | $269 |
| NEW World Medical,inc. | 2 | $185 |
| Aerie Pharmaceuticals, Inc. | 1 | $139 |
| Rxsight Inc | 1 | $105 |
| Alcon Puerto Rico Inc | 2 | $86 |
| Sight Sciences, Inc. | 1 | $79 |
| Alcon | 1 | $52 |
| Amgen | 2 | $46 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- XEN GLAUCOMA TREATMENT SYSTEM$250
- Rocklatan$139
- Rhopressa$139
- XEN$125
- MIEBO$125
- XIIDRA$125
- Kahook Dual Blade$114
- Clearpath$114
- Ahmed Glaucoma Valve$114
- Streamline$114
- RXSIGHT CONTACT LENS$105
- RXSIGHT INJECTOR CARTRIDGE$105
- RXSIGHT INJECTOR HANDPIECE$105
- RXSIGHT LIGHT DELIVERY DEVICE (LDD)$105
- LIGHT ADJUSTABLE LENS (LAL)$105
How this compares
$1,628 in reported general payments places this provider in the 70th percentile of 214 ophthalmology providers in Puerto Rico.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| LumiganBimatoprost | 966 | $259,671 |
| Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol | 324 | $55,290 |
| CombiganBrimonidine Tartrate/Timolol | 173 | $40,580 |
| RestasisCyclosporine | 56 | $34,177 |
| VyzultaLatanoprostene Bunod | 120 | $31,044 |
| AzoptBrinzolamide | 67 | $25,491 |
| Alphagan PBrimonidine Tartrate | 104 | $24,862 |
| Fluorometholone | 373 | $24,071 |
| Brimonidine Tartrate | 654 | $20,876 |
| Prednisolone Acetate | 546 | $20,841 |
| SimbrinzaBrinzolamide/Brimonidine Tart | 89 | $18,701 |
| Latanoprost | 1,117 | $15,782 |
| Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat | 477 | $15,714 |
| Dorzolamide Hcl | 384 | $12,219 |
| Travoprost | 90 | $12,084 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieLumigan, Combigan, Restasis, Alphagan P | $667 | $359,2901,299 claims |
| AlconAzopt, Simbrinza | $52 | $44,192156 claims |
| Bausch & Lomb Americas Inc.Vyzulta | $269 | $31,044120 claims |
| Aerie Pharmaceuticals, Inc.Rocklatan | $139 | $4,88414 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 214 ophthalmology providers in Puerto Rico.
Other ophthalmology in Rio Piedras
- Armando OliverRio Piedras$251K
- Maria Berrocal FernandezSan Juan$547K
- Jose MontesSan Juan$396K
- Andres Emanuelli AnzalottaCorozal$50K
- Cristobal Cruz-ColonPonce$44K
- Juan Nevarez MarreroSan Juan$19K
- Natalio Izquierdo EncarnacionSan Juan$16K
- Ian PiovanettiSan Juan$11K
- Antolin Alvarez PontSanturce$10K
- Jaime Bravo CastroSan Juan$8K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.